Trump-backed plan could fast-track psychedelic therapies — here’s what to know
Former US President Donald Trump signed an executive order to fast-track research and potential FDA approval of psychedelics for treating mental health conditions. The move has drawn mixed reactions from doctors and experts, with some praising its potential to transform mental health treatment and others warning about limited evidence on safety and effectiveness.
Former US President Donald Trump signed an executive order to fast-track research and potential FDA approval of psychedelics like ibogaine, psilocybin, and MDMA for treating PTSD, depression, and addiction. The order aims to advance mental health treatments, particularly for veterans. Doctors are divided on the move, with some supporting its potential to transform mental health treatment and others warning about limited evidence on safety and effectiveness. Psychedelics are being studied in controlled clinical settings for mental health treatment. Experts emphasize that these therapies need further research to determine safe doses and indications. The executive order requires the VA Health System to begin psychedelics research and clinical trials, making psychedelics available to veterans who have not responded to traditional treatments.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.